Delving into the Latest Updates on Merck Santé SASU with Synapse

Even at the disease onset, about 70% of patients with multiple sclerosis (MS) suffer from cognitive impairment that impacts quality of life. Currently, some speed processing tests are used, such as SDMT ( symbol digit modalities test ), CSCT (information treatment speed evaluation) and WAIS-IV (Weschler Adult Intelligence Scale ). Their inconvenient are the improvement of scores in test-retest, and some difficulties doing the tests due to motor or visual impairment that might be reported. The XO test is fast, cheap and easy to use during medical consult by neurologists. It seems to be correlated to results of speed processing tests, and probably to some executive functions tests too. Asthenia, anxiety, depression and pain are likely to have a negative influence on tests results. Screening every patients with a short test aims to detect patients with cognitive impairment earlier. After a positive screening test, and to better characterize cognitive impairment, they will undergo a neuropsychological test battery. Depending on the alteration, adapted workstation, financial support, technical and human helps will be implemented in order to improve the daily-living of patients.
This study aims to approve the XO as a screening test of cognitive impairment in MS patients. We will study the relationship between XO test, and SDMT, CSCT, WAIS-IV, and also with questionnaires about pain, asthenia (FSS, Fatigue Severity Scale), anxiety and depression (HAD, Hospital Anxiety and Depression ). The XO test will be standardized using a healthy population.

开始日期2019-07-08

申办/合作机构

Centre Hospitalier Universitaire de Clermont Ferrand

[+1]

EUCTR2006-005006-31-FR / Unknown statusN/A

A randomized, stratified on age, parallel group design study to investigate the safety, tolerability and pharmacokinetics after a 60 minutes application of 4% lidocaine cream compared to EMLA® cream for local anaesthesia in 40 children in need of scheduled surgery.

开始日期2007-04-03

申办/合作机构

Merck Santé SASU

100 项与 Merck Santé SASU 相关的临床结果

登录后查看更多信息

0 项与 Merck Santé SASU 相关的专利（医药）

登录后查看更多信息

6

项与 Merck Santé SASU 相关的文献（医药）

2005-07-01·Journal of Endocrinology3区 · 医学

Short-term treatment with mycophenolic acid and tacrolimus is tolerogenic for INS-1 cell clone transplantation and the deleterious effects of the drugs are limited: in vivo and in vitro studies

3区 · 医学

Article

作者: Charon, C. ; Asfari, M. ; Audet, A. ; Coffy, S. ; Kergoat, M. ; Berta, S.

One of the major requirements for a successful and life-lasting organ transplant is the access to safe, least toxic and permanent tolerance-inducing drugs. In this study we wished to evaluate the effects of tolerogenic doses of the immunosuppressive drugs mycophenolic acid (MPA) and tacrolimus (Tac) on clonal β-cell lines, both in vivo and in vitro. Here we demonstrate that combined administration of low-dose MPA and Tac for 23 days induced permanent tolerance in an allogeneic β-cell line transplant in Wistar rat liver through the portal vein. This short-term treatment of tolerogenic doses of the two drugs was deleterious to the survival of the transplanted cells but a small percentage of the cells could resist the effect and become fully active when the drugs were removed. The surviving cells, retrieved from growth in vivo, did not exhibit increased resistance in comparison to the original cells when tested in vitro at two glucose concentrations, 10 and 20 mM. The presence of a small percentage of resistant cells at the two glucose concentrations was also detected in the in vitro study after a continuous 8-day treatment demonstrating that the in vivo resistance was not related to micro-environmental protection but possibly to a phenotypic cell state that is yet to be determined.

2003-01-01·Current Medical Research and Opinion4区 · 医学

The development of an oralantidiabetic combination tablet: design, evaluation and clinicalbenefits for patients with type 2diabetes

4区 · 医学

Article

作者: Nicholson, G. ; Porte, F. ; Howlett, H. ; Allavoine, T. ; Kuhn, T.

Type 2 diabetes is a chronic and progressive disease. Oral antidiabetic monotherapies directly address only one defect as their primary mechanism of action, and do not control blood glucose sufficiently well to meet current glycaemic targets. In consequence, most patients need combination therapy within a few years. However, the co-administration of two or more oral antidiabetic drugs may render treatment regimens difficult to follow. Combining oral antidiabetic agents into a single tablet provides a means of intensifying antidiabetic therapy while supporting good patient compliance. An insulin sensitiser and an insulin secretagogue represent a rational oral antidiabetic combination, as they address the dual endocrine defects of insulin resistance and impaired beta-cell function in type 2 diabetes. Nevertheless, the components of a combination tablet must be carefully chosen. Metformin (an insulin sensitiser) and glibenclamide (an insulin secretagogue) are well supported by decades of clinical evidence, and the pharmacokinetics of these agents support twice-daily co-administration. The final technical challenge is to optimise their delivery within a single-tablet combination. A recently-introduced metformin-glibenclamide combination tablet (Glucovance) has been extensively studied in well-designed clinical trials, where it has been shown to be more effective than its component monotherapies in controlling fasting and postprandial glycaemia. This treatment provides a case study in the development of a single-tablet oral antidiabetic combination, in terms of the pharmacokinetic issues facing the development of this preparation, and the implications of the pharmacokinetic properties of the components of the combination tablet on their pharmacodynamic actions and risk-benefit profile.

EMD 336340, a substituted pentadienoic acid, as a novel balanced activator of PPAR alpha and gamma

作者: Contard, Francis ; Guyard-Dangremont, Valerie ; Zeiller, Jean-Jacques ; Berthelon, Jean-Jacques ; Brunet, Michel ; Guerrier, Daniel ; Dupont, Herve

A new series of substituted pentadienoic acids was synthesized as potential hypoglycemic and hypolipidemic agents.The synthesis of one representative of this new chem. family, EMD 336340 (LM 4156), is described.EMD 336340 activated both PPAR α and γ receptors in an in vitro cellular model using Gal4-hPPAR chimera.In vivo the activity has been shown in db/db mouse, a predictable model of Type 2 diabetes.This balanced effect offers a potential monotherapy in the management of hyperglycemia and dyslipidemia in type 2 diabetic patients.

100 项与 Merck Santé SASU 相关的药物交易

登录后查看更多信息

100 项与 Merck Santé SASU 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

1

7

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

盐酸二甲双胍 ( PRKAB1 )	2型糖尿病更多	批准上市
CRE-10904	高血压更多	终止
LCB-2853 ( TBXA2R )	血栓形成更多	无进展
LM-3339 ( Kv7.2 )	哮喘更多	无进展
LR-90 ( PPAR )	高脂血症更多	无进展